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Electronic alerts to prevent venous thromboembolism among hospital-
ized patients
Kucher N, Koo S, Quiroz R, et al. N Engl J Med 2005;352:969-77.
Conclusion: A computer-based program to alert physicians regarding
the use of venous thromboembolism (VTE) prophylaxis markedly reduced
rates of pulmonary embolism and deep venous thrombosis (DVT) in hospi-
talized patients at risk for VTE.
Summary: The authors hypothesized that use of a computer alert
program to alert physicians regarding hospitalized patients at high risk for
VTE might reduce the frequency of DVT by increasing the frequency of
prophylaxis. A computer program was developed linked to a patient database
to identify hospitalized patients at risk for VTE. The patients were randomly
assigned to an intervention group in which the treating physician was made
aware of the patient’s risk of VTE (n 1255) or to a control group in which
no such alert was issued (n  1251). Physicians receiving the alert for VTE
prophylaxis were required to acknowledge the alert and could then order or
withhold prophylaxis according to clinical judgment. Prophylaxis included
graduated compression stockings, pneumatic compression boots, unfrac-
tionated heparin, warfarin, or low-molecular-weight heparin. Clinically di-
agnosed, objectively confirmed VTE (DVT or pulmonary embolism) at 90
days was the primary end point.
There was a greater use of mechanical prophylaxis in the intervention
group (10.0% vs 1.5%; P  .001) and a greater use of pharmacologic
prophylaxis in the intervention group (23.6% vs 13.0%; P  .001). There
were 103 (8.2%) primary end points in the control group and 61 (4.9%) end
points in the intervention group. Freedom from VTE at 90 days was 94.1%
(95% CI, 92.5%-95.5%) in the intervention group vs 90.6% (95% CI,
88.7%-92.2%; P  .001) in the control group. The risk of VTE at 90 days
was reduced by 41% with the computer alert system (hazard ratio, 0.59; 95%
CI, 0.43-0.81; P  .001).
Comment:The necessity of VTE prophylaxis in hospitalized patients is
widely acknowledged, yet VTE prophylaxis is underused. This study indi-
cates that VTE prophylaxis can be increased and clinically evident VTE
events decreased through use of a physician alert system that notifies
physicians as to the patient’s VTE risk. Despite this, it is also clear that
because only 33.5% of patients in the intervention group received prophy-
laxis, additional measures will be required to maximize VTE prophylaxis in
hospitalized patients.
Statins decrease perioperative cardiac complications in patients under-
going non-cardiac vascular surgery
The Statins for Risk Reduction in Surgery (StaRRS) Study. J Am Coll
Cardiol 2005;45:336-42
Conclusion: Statins are highly protective against perioperative cardiac
complications in patients undergoing vascular surgery.
Summary: The authors sought to assess whether statins can decrease
cardiac complications in patients undergoing noncardiac vascular surgery.
This was a retrospective study that recorded patient history, admission
medications, and other patient characteristics in patients undergoing carotid
endarterectomy, lower extremity revascularization, or abdominal aortic an-
eurysm repair from January 1999 to December 2000. Data were derived
from a tertiary medical center. Perioperative complications of death, myo-
cardial ischemia, myocardial infarction, congestive heart failure, and ventric-
ular tachyarrhythmias were recorded. Predictors of perioperative cardiac
complications and potential medications that may confer a protective benefit
for perioperative cardiac complications were analyzed by using univariate
and multivariate logistic regression analysis. There were 157 complications
in 1163 eligible hospitalizations. There were significantly fewer complica-
tions in patients receiving statins (9.9%) than in those not receiving statins
(16.5%; P  .001). The difference between the two groups was mostly due
to the occurrence of congestive heart failure and myocardial ischemia.
Adjustment for significant predictors of perioperative complications such as
age, sex, type of operation, previously known left ventricular dysfunction,
and diabetes still resulted in statins conferring a highly significant protective
effect (odds ratio, 0.52; P  .001).
Comment: It is now well appreciated that statins have significant
pleotrophic effects in addition to decreasing lipid levels. This article does
not indicate when statins need to be started before an operation or how
long they need to be continued after an operation. If vascular surgeons
are going to prescribe statins to reduce perioperative complications, they
must then be prepared to monitor the drugs’ potential side effects and
complications. Alternatively, they must communicate with primary care
physicians to ensure that the medications are properly used and the
patients adequately followed up.
Prospective randomised study of Endovenous Radiofrequency Oblit-
eration (Closure) Versus Ligation and Vein Stripping (EVOLVeS):
2-year follow-up
Lurie F, Creton D, Eklof B, et al. Eur J Vasc Endovasc Surg 2005;29:67-73.
Conclusion: At 2 years, closure of the greater saphenous vein (GSV)
with radiofrequency obliteration provides results at least equal to those of
high ligation and stripping of the GSV.
Summary: EVOLVeS is a small, prospective, randomized study that
compared radiofrequency obliteration of the GSV with high ligation and
stripping of the GSV in patients with symptomatic varicose veins or GSV
incompetence and who were candidates for either conventional vein strip-
ping or radiofrequency obliteration of the GSV. There were five participat-
ing sites: two in France, one in Austria, and two in the United States. A total
of 85 patients were entered into the study, with 46 limbs allocated to
radiofrequency obliteration and 40 limbs to high ligation and stripping.
Eighty limbs received treatment. This article reports intermediate clinical
outcomes, rates of recurrent varicosities and neovascularization, follow-up
ultrasound changes of the GSV, and quality-of-life changes in the patients
participating in the trial. There were 45 patients re-examined at 1 year and
65 patients re-examined 2 years after treatment. At follow-up, patients were
classified with regard to the CEAP classification for chronic venous disease
and had calculation of venous clinical severity scores. Ultra sound examina-
tions and quality-of-life assessments were also performed. There were no
differences in the CEAP classifications or venous clinical severity scores in the
two groups at 1 and 2 years. Of the GSV trunks occluded by radiofrequency
ablation, 51% underwent progressive shrinkage of the GSV diameter over 2
years. An additional 41% of the GSVs became undetectable by ultrasound at
the 2-year follow-up. Two patients with initially closed GSVs by the closure
technique had reopening of the vein. Neovascularization was found in one
radiofrequency obliteration case and in four stripping and ligation cases. At
1 and 2 years of follow-up, there was a cumulative rate of recurrence of
varicose veins of 14% in the radiofrequency obliteration group and 21% in
the stripping and ligation group (not significant). Global quality-of-life
scores were in favor of radiofrequency ablation at 1 and 2 years after
treatment. Pain was the only quality-of-life variable consistently reduced in
the radiofrequency group.
Comment: This is another piece of evidence suggesting that, at least in
the short term, catheter-based interventions for obliteration of the GSV are
at least as effective as traditional ligation and stripping procedures. There are
still details to be worked out regarding catheter-based obliterations of the
GSV, such as the long-term effects of preservation of the proximal greater
saphenous branches and when and if to combine stab phlebectomy or
sclerotherapy with catheter-based treatment of the GSV.
Increased growth rate of abdominal aortic aneurysms in women, the
Tromso Study
Solberg S, Singh K, Wilsgaard T, et al. Eur J Vasc Endovasc Surg 2005;29:
145-9.
Conclusion: Female sex is an independent predictor for increased
growth rate of an abdominal aortic aneurysm (AAA).
Summary: The Tromso Study is a population-based study emphasiz-
ing cardiovascular disease. It began in 1974. In this component of the study,
men and women age 55 to 74 years were eligible for examination of their
abdominal aorta with ultrasound. An AAA was considered to be present if
the abdominal aorta was greater than 3.5 cm in diameter, there was a
localized dilatation of the infrarenal aorta, or there was a 5-mm increase of
the infrarenal abdominal aorta compared with the diameter of the aorta at
the level of the renal arteries. If these criteria were met, then the patient was
referred to have a CT scan of the abdominal aorta. Patients underwent
surgery for an abdominal aortic diameter of 5.5 cm or more. There were 348
patients identified with AAA. Fourteen did not attend CT scan follow-up,
and 31 were initially operated on because of the size of the aneurysm.
Forty-seven additional patients were believed as a result of CT scanning to
have a nonaneurysmal aorta. An additional 22 patients were lost to follow-
up. There were therefore 185 men and 49 women eligible for follow-up.
These subjects were followed up with ultrasound examination of the aorta
every 3 to 6 months from the beginning of this study in 1994/1995 to study
completion on December 31, 2002. During follow-up, 49 patients under-
went operation because of aneurysm growth, and 48 patients died without
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surgery for their AAA. Mean follow-up was 62.4 months (range, 3-90
months).
There were a mean of 16.1 ultrasound examinations per patient, with a
total follow-up of 14,544 patient-months and a total of 3773 ultrasound
examinations performed. The overall aneurysm growth rate was 1.82  2.1
mm per year. The mean growth rate was 0.58 mm per year for aneurysms
with initial diameter less than 2.5 cm and 2.63 mm per year for aneurysms
with an initial diameter larger than 4.9 cm. The mean growth rate for women
was 2.43 2.95 mm per year, and for men it was 1.65 1.78 mm per year.
Adjusting for age and initial diameter, the mean annual growth rate was 0.7
mm per year lower in men than in women (P  .003). Of the multiple risk
factors for aneurysm growth analyzed, only initial aneurysm diameter and
female sex were independently predictive of an increased growth rate of
AAA.
Comment: Evidence is accumulating that AAA disease is different in
men than in women. Previous studies have suggested that potential for
aneurysm rupture for the same diameter aneurysm may be higher in women
than men. This study is the first to suggest that aneurysm expansion rates
may also be higher in women than in men. If this observation is confirmed in
a larger series, it will have significant implications for screening and fol-
low-up of AAA in women.
A randomized trial of low-dose aspirin in the primary prevention of
cardiovascular disease in women
Ridker PN, Cook NR, Lee I-M, et al. N Engl J Med 2005;352:1293-304.
Conclusion: In initially healthy women 45 years of age or older, aspirin
decreases the risk of stroke without affecting the risk of myocardial infarction
or overall death from cardiovascular causes.
Summary: Aspirin is known to be effective in treatment of acute
myocardial infarction and in secondary prevention of cardiovascular disease
in both men and women (BMJ 2002;324:71-86). In addition, trials have
indicated that low-dose aspirin is effective in primary prevention of myocar-
dial infarction in men without a significant effect on ischemic stroke. There
are, however, few data with respect to aspirin use and primary prevention of
cardiovascular disease in women. In this article, 39,876 women 45 years of
age or older and considered healthy at study entrance were randomized to
receive 100 mg of aspirin or placebo on alternate days. They were followed
up for 10 years for a first major cardiovascular event (death from cardiovas-
cular cause, nonfatal myocardial infarction, or nonfatal stroke). In follow-up,
there were 477 major cardiovascular events in the aspirin group and 522 in
the placebo group. This 9% reduction in risk with aspirin was not significant
(relative risk [RR], 0.91; 95% confidence interval [CI], 0.80-1.03; P .13).
There was a 17% reduction in risk of stroke in the aspirin patients vs those
treated with placebo (RR, 0.83; 95% CI, 0.69-0.99; P .04). This resulted
from a 24% reduction in risk of ischemic stroke (RR, 0.76; 95% CI,
0.63-0.93; P  .009). There was a nonsignificant increase in risk of hemor-
rhagic stroke in the aspirin group (RR, 1.24; 95% CI, 0.82-1.87; P  .31).
Aspirin had no significant effect on risk of fatal or nonfatal myocardial
infarction. Gastrointestinal bleeding leading to transfusion was more fre-
quent in the aspirin than in the placebo group (RR, 1.40; 95% CI, 1.07-
1.83; P .02). Subgroup analysis indicated that the most consistent benefit
for aspirin occurred in women 65 years of age or older at study entry. In
these women, the risk of major cardiovascular events was reduced by 26% in
the aspirin group (P .008), and the risk of ischemic stroke was reduced by
30% (P .05). Also, myocardial infarction was decreased by aspirin use (P
.04).
Comment: The study, when considered with other studies, suggests
basic biologic differences in the response of women and men to aspirin. The
findings are essentially opposite those of the Physician’s Health Study
(N Engl J Med 1989;321:129-35). In the Physician’s Health Study, aspirin
reduced the risk of myocardial infarction in men 50 years of age or older and
had no effect on the risk of stroke. The biologic basis for these differing
results is unknown. The reader is referred to an excellent editorial accompa-
nying this article (N Engl J Med 2005;52:1366-8) that speculates on the
biologic cardiovascular differences between men and women.
Randomized clinical trial of the antiplatelet effects of aspirin, clopi-
dogrel combination versus aspirin alone after lower limb angioplasty
Casser K, Ford I, Greaves M, et al. Br J Surg 2005;92:159-65.
Conclusion: The combination of aspirin and clopidogrel provides
greater platelet function inhibition than aspirin alone when used in patients
with claudication treated with angioplasty.
Summary: The study investigated the antiplatelet effects of aspirin and
clopidogrel compared with aspirin alone in patients with claudication who
underwent endovascular revascularization. A total of 132 patients were
entered into this double-blind, randomized, placebo-controlled trial. Pa-
tients were treated with clopidogrel and aspirin or aspirin and placebo with
a loading dose administered 12 hours before the endovascular intervention.
Platelet function was determined by flow cytometric measurements of
platelet fibrinogen binding and P-selectin expression. Measurements were
taken at baseline, 12 hours after administration of the loading dose, and 1
hour, 24 days, and 30 days after the endovascular intervention. Analysis was
on an intention-to-treat basis.
Platelet activation in the clopidogrel group decreased within 12 hours
of the loading dose (P selectin by 27.3%, P  .017; fibrinogen binding by
34.7%, P  .024; stimulated fibrinogen binding by 49.2%, P  .001). No
changes were observed in the placebo group. Compared with baseline,
platelet function in the clopidogrel group was suppressed at 1 hour, 24
hours, and 30 days after vascular intervention (stimulated fibrinogen bind-
ing by 53.9%, 51.7%, and 57.2%, respectively; P  .001 in all cases). One
hundred twenty-five of the 132 patients randomized in the study proceeded
to angiography, and 103 actually underwent vascular intervention. Twenty-
two patients had no intervention because endovascular intervention was
deemed not feasible or too risky. Four patients in the placebo group stopped
taking the medication early, and seven patients in the clopidogrel group
stopped taking the medication early. More patients developing bruising at or
around the access site in the clopidogrel group (25 vs 16), but the difference
was not statistically different. There were no differences in rates of fatal
bleeding, bleeding requiring surgical intervention, or hemorrhagic stroke
between the two groups.
Comment: The use of clopidogrel in conjunction with endovascular
procedures has, in many centers, become the standard of care. This study
indicates that clopidogrel in combination with aspirin provides a greater
antiplatelet effect than aspirin alone in patients undergoing lower ex-
tremity endovascular procedures. The incidence of minor bleeding prob-
lems is probably higher with clopidogrel and aspirin than aspirin alone.
Others have also shown that the combination of aspirin and clopidogrel
results in a higher risk of major bleeding than aspirin alone (JAMA
2002;288:2411-20). The authors did not address the clinical question in
patients undergoing angioplasty of whether periprocedural clopidogrel
and aspirin provide improved short- and long-term angioplasty patency
compared with aspirin alone.
Elastin and calcium rather than collagen or lipid content are associated
with echogenicity of human carotid plaques
Goncalves I, Lindholm MW, Pedro LM, et al. Stroke 2004;35:2795-800.
Conclusion: Elastin and calcium, but not collagen or lipid, are the
primary determinants of echogenicity of carotid plaques. Echolucency is
associated with higher elastin contents.
Summary: Histologic studies have suggested that echogenic plaques
are characterized by fibrosis and calcification, whereas echolucent plaques
are lipid rich with hemorrhage. Echolucent plaques have been associated
with increased stroke risk. The authors sought to relate echogenicity of
carotid plaques to plaque composition as analyzed biochemically. Standard-
ized high-definition ultrasound was used to classify the echogenicity of
human carotid plaques. Plaques were considered echolucent with grayscale
median values less than 32 and echogenic with grayscale median values
greater than 32. High-performance thin-layer chromatography and fast-
performance liquid chromatography were used to determine the biochemi-
cal composition of plaques. Biochemical analysis suggested that echolucent
plaques contained less hydroxyapatite (P  .018), more total elastin (P 
.008), and more intermediate-size elastin forms (P  .018) than echogenic
plaques. Echogenic and echolucent plaques did not differ in collagen con-
tent when analyzed biochemically or histologically. Triglycerides, choles-
terol esters, and unesterified cholesterol were increased in carotid plaques
associated with symptoms (P  .04). Cholesterol ester content, esterified
cholesterol, and triglycerides did not differ between echolucent and echo-
genic plaques.
Comment: This is the first study to relate carotid plaque echogenicity
to a biochemical analysis of plaque composition. The results suggest that
calcification, rather than collagen content, is the prime determinant of
plaque echogenicity. This report is in contradiction to previous reports of
histologic analysis relating echogenicity to fibrous tissue content.
The role of color duplex sonography in the diagnosis of giant cell
arteritis
Romera-Villegas A, Vila-Coll R, Poca-Dias B, et al. J Ultrasound Med
2004;23:1493-90.
Conclusion: High-resolution color duplex sonography may replace
biopsy in diagnosis of giant cell arteritis.
Summary: Temporal artery biopsy is frequently used to confirm a
diagnosis of giant cell arteritis. The authors sought to assess the usefulness of
color duplex sonography as an alternative to temporal artery biopsy in the
diagnosis of giant cell arteritis. Sixty-eight consecutive patients with a clinical
history suggestive of active temporal arteritis were studied with color duplex
sonography and temporal artery biopsy. The mean age of the patients was 77
years. There were 48 women and 20 men. Temporal artery morphologic
characteristics were studied with color duplex sonography by using a linear
array transducer (5-10 MHz) before temporal artery biopsy. Duplex studies
were assessed for the presence of a hyperechoic halo around the temporal
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